The Karoon Energy Ltd (ASX: KAR) share price is in focus after its half-year results, which saw sales revenue reach US$244.9 million and an interim dividend declared at 1.2 cents per share fully franked.

What did Karoon Energy report?

• First half FY26 sales revenue of US$244.9 million (down 21% year-on-year)
• Underlying EBITDAX of US$129.7 million (down 35%)
• Underlying net profit after tax (NPAT) of US$29.2 million; statutory NPAT of US$26.7 million
• Interim dividend of 1.2 cents per share fully franked (down 50%)
• US$15.3 million spent on share buybacks (11.8 million shares at an average A$1.84/share)
• Major Baúna investment campaign completed, and Who Dat East project sanctioned

What else do investors need to know?

Karoon wrapped up a significant capital project at Baúna, designed to improve long-term performance and bring key wells back online. While production and sales volumes were lower due to planned outages and a riser issue at Who Dat, the company benefited from stronger realised oil prices, with around 97% of sales being oil or liquids and no hedging in place.

Production costs dropped from US$74.0 million to US$59.3 million, mainly because Karoon now owns the Baúna FPSO, removing lease charges. Net debt increased to US$269.7 million, reflecting heavy first-half investment, but management expects cash outflows and debt to ease in the second half, provided oil prices and operations stay on track.

What did Karoon Energy management say?

Ms Carri Lockhart, Chief Executive Officer and Managing Director, commented:

In 1H26, Karoon undertook its largest ever program of capital projects at Baúna in Brazil, designed to enhance the future performance of the Baúna FPSO and bring two important wells back into production. All key Baúna activities have now been successfully delivered, with an excellent personal safety performance maintained throughout, positioning the Company for improved operating performance in 2H26…

We enter the second half in a strong position, with a low-cost asset base, restored production at Baúna and a robust balance sheet. Our core objectives remain unchanged, focused on ensuring safe, reliable and efficient operations, mitigating natural decline from our two long-life assets, advancing our growth opportunities and maintaining capital discipline to create shareholder value.

What’s next for Karoon Energy?

Looking ahead, Karoon expects lower cash outflows and is on track to deliver annual cost savings of US$30–40 million following the FPSO purchase. A decision to progress with Front-End Engineering and Design for the Neon project is expected by the end of the year, while development of Who Dat East will commence after its recent approval.

2026 full-year guidance now includes increased capex for Who Dat East, with total production forecast between 7.2 and 8.2 million barrels of oil equivalent. Further work is underway on high-potential assets in Brazil and the US.

Karoon Energy share price snapshot

The Karoon Energy share price has underperformed the S&P/ASX 200 index (ASX: XJO) over the past 12 months with a decline of 9%.

View Original Announcement

The post Karoon Energy half-year earnings: FY26 results and outlook appeared first on The Motley Fool Australia.

More reading

• Karoon Energy share price on watch: Who Dat East project gets green light
• Here are the top 10 ASX 200 shares today
• Downgrade alert! 6 ASX 200 shares marked down by experts this week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Emerald Resources NL (ASX: EMR) share price was in focus on Wednesday after the company revealed a record full-year profit of $259.6 million, driven by higher gold prices and disciplined operations. Revenue jumped 40% to $612.3 million, as gold production from Okvau reached more than 100,000 ounces with costs among the lowest in the sector.

What did Emerald Resources report?

• Revenue: $612.3 million, up 40% from FY25
• Net profit after tax (NPAT): $259.6 million, up 196%
• EBITDA: $392.1 million, up 93% year on year
• Gold production: 100,405 ounces at an all-in sustaining cost (AISC) of US$972/oz
• Cash, bullion and investments: $491.1 million at 30 June 2026
• Dividends: No dividend declared for FY26

What else do investors need to know?

Emerald remained debt-free and unhedged, cementing its position as a low-cost gold producer. Operational highlights included expanding reserves and robust gold recoveries from the Okvau mine in Cambodia, now totalling over 509,600 ounces since production began in 2021. Growth activities ramped up across both Cambodia and Australia, supported by a strong balance sheet.

Beyond Okvau, significant progress was made on the Dingo Range and Memot projects. Both are fully permitted, with maiden ore reserve estimates to follow and studies well underway. Exploration continues to deliver promising results, leading to resource upgrades and demonstrating future growth pathways.

What’s next for Emerald Resources?

Looking ahead to FY27, Emerald expects gold production of 100,000–115,000 ounces at Okvau, with similar AISC guidance and the addition of new feed sources through further drilling. Development is progressing for both the Dingo Range (Western Australia) and Memot (Cambodia) projects, with definitive feasibility studies nearing completion and first mining activities on track for the coming year.

Exploration remains a priority, with over 3.9 million ounces now in global resources across key projects. Emerald continues to target becoming a multi-mine, 300,000–400,000 ounce per annum gold producer, backed by a solid cash position and expanding project pipeline.

Emerald Resources share price snapshot

The Emerald Resources share price has risen strongly in the past 12 months, smashing the S&P/ASX 200 index (ASX: XJO) with a gain of almost 85%.

View Original Announcement

The post Emerald Resources FY26 earnings: Record profit on gold price surge appeared first on The Motley Fool Australia.

More reading

• Emerald Resources delivers solid Q4 production and advances key projects

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Sigma Healthcare Ltd (ASX: SIG) share price is in focus today after the company reported a 15.5% lift in revenue to $10.8 billion and a 20.6% surge in normalised EBIT to $1.09 billion for FY26, its first full-year result since merging with Chemist Warehouse Group.

What did Sigma Healthcare report?

• Revenue: $10.8 billion, up 15.5% year on year
• Normalised EBIT: $1,090.0 million, up 20.6%, with margin rising to 10.1%
• Normalised NPAT: $732.3 million, up 22.3%
• Net debt reduced to $663 million (Debt to Normalised EBITDA: 0.57x)
• Integration synergies delivered: $32.6 million, aiming for $100 million p.a. by FY29
• Fully franked final dividend: 2.0 cents per share (full year: 4.0 cents per share)

What else do investors need to know?

Sigma’s Australian business remains its “engine room”, contributing $10.4 billion in revenue and $1,034.2 million in normalised EBIT. The international arm is gathering momentum, delivering 33% revenue growth and doubling EBIT, with Ireland now profitable and a push into the UK market underway.

Sigma added 24 Chemist Warehouse branded stores in Australia, reaching 561 stores, while opening 20 new international outlets. The company continued to expand its own and exclusive-label products, with annual sales near $1 billion and the Wagner Pharmaceuticals generic business growing over 30%.

What did Sigma Healthcare management say?

Sigma’s CEO, Vikesh Ramsunder, said:

FY26 demonstrates that Sigma is not simply larger after the merger, it is structurally stronger. Our highly scalable business model is underpinned by defensive industry characteristics. With the Australian infrastructure already in place and a clearly defined runway to keep growing, we are confident the model will keep compounding value.

What’s next for Sigma Healthcare?

Sigma’s FY27 agenda centres on growing its network, driving operating leverage, and boosting product differentiation. The company aims to open 13 new Chemist Warehouse stores in Australia and 19 internationally in the first half, including its entry into the UK. Refreshed growth in the Amcal and Discount Drug Stores brands is also expected, with 42 new Australian stores on the way.

With a capital-light model and a solid balance sheet, Sigma is targeting sustained growth and long-term shareholder value, with over half of planned synergy savings still to be realised.

Sigma Healthcare share price snapshot

The Sigma Healthcare share price has underperformed the S&P/ASX 200 index (ASX: XJO) on a 12-month basis with a decline of almost 7%.

View Original Announcement

The post Sigma Healthcare FY26 earnings: Record profit as Chemist Warehouse merger delivers growth appeared first on The Motley Fool Australia.

More reading

• My top 5 ASX 200 shares to buy and hold
• Why I’d buy Coles, Telstra and this ASX 200 blue chip share for retirement
• ASX 200 technology and healthcare shares continued their comeback last week
• 3 ASX 200 blue-chip shares I’d buy now

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.